Salute e Benessere

Zenas BioPharma Appoints Patricia Allen to its Board of Directors

“We are pleased to welcome Patty to our Board of Directors,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas BioPharma. “She has successfully led cross-organizational functions and served on the board of directors of both private and public global biotechnology companies. We look forward to Patty's contributions to the next phase of Zenas' growth as we advance our mission to develop and commercialize transformative immunology-based therapies for patients in need.” “I...
Nasdaq GlobeNewswire
06/03/2024

TECHTRONIC INDUSTRIES DELIVERS SOLID 2023 ANNUAL RESULTS

million million million Changes *For the year endedDecember 31, 2023 Gross margin improved 14 bps to 39.5% in 2023. This gross margin improvement is highly encouraging given the significantUS$987 millioninventory reduction versus last year. EBIT was atUS$1.1 billion, 5.5% lower than 2022. In the second half of 2023, EBIT improved toUS$575 million, a 1.1% increase versus the second half of 2022. TTI deliveredUS$976 millionof net profit. The decline of...
PR Newswire
06/03/2024

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of…

New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZA Reductions in biomarker complement previously reported RESPOND efficacy results showing improved motor function in most participants treated with SPINRAZA after gene therapy CAMBRIDGE, Mass., March06, 2024(GLOBE NEWSWIRE) --Biogen Inc.(Nasdaq: BIIB) announced interim 6-month biomarker data from the initial 29...
Nasdaq GlobeNewswire
06/03/2024

ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes…

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for...
Nasdaq GlobeNewswire
06/03/2024

iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors

“Expanding our board with industry leaders and oncology veterans with commercial, scientific, and corporate portfolio strategy experience is of the utmost importance for iTeos. After the recent appointment of Servier's David Lee, we are thrilled to welcome Jill DeSimone to our Board of Directors during an important time in iTeos' evolution. Jill and David's unique insights will be of tremendous value to our organization as we continue on our path to becoming a late-stage biopharmaceutical...
Nasdaq GlobeNewswire
06/03/2024

ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results…

To access the conference call, please registerhere. Registrants will receive the dial-in number and unique PIN. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under “Events and Presentations” in the Investors section of the ADC Therapeutics website atir.adctherapeutics.com. The archived webcast will be available for 30 days following the call. About ADC Therapeutics ADC Therapeutics...
Nasdaq GlobeNewswire
06/03/2024

iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides…

- Multiple clinical milestones across portfolio anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - Completed enrollment of third dose cohort in Phase 1 trial of EOS-984 - Preclinical presentations on role of ENT1 at SITC Spring Scientific and profile of EOS-984 at AACR annual meeting - Cash and investment balance of $632.7 million as of December 31, 2023 expected to provide runway through 2026 across a number of impactful...
Nasdaq GlobeNewswire
06/03/2024

Antion Biosciences announces latest data and validation of its technology…

In vivo Proof-of-Concept demonstrated for its off-the-shelf miCAR7 T-cell product, data presented at the 7 thCAR-TCR Summit EuropeMilestone achieved in its collaboration with Allogene TherapeuticsGENEVA, March06, 2024(GLOBE NEWSWIRE) -- Antion Biosciences (Antion), a Geneva-based cell and gene therapy company developing off-the-shelf and universally applicable cellular immunotherapies, announces achievement of two significant milestones that underscore the uniquely...
Nasdaq GlobeNewswire
06/03/2024

BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and…

MAINZ, Germany, March 6, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2023 on Wednesday, March 20, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.To access the live conference call via...
Nasdaq GlobeNewswire
06/03/2024

Bioceramics Market worth $10.2 billion by 2028 - Exclusive Report by…

Browse in-depth TOC on "Bioceramics Market" Browse in-depth TOC on "Bioceramics Market" 206 – Tables 63 – Figures 233 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=157878452 The Zirconia material segment accounted for the largest market share in 2022, in terms of value. Zirconia is one of the four most popular bioceramics in the world. Zirconia can be composed of various materials and dopants to achieve specific properties...
PR Newswire
06/03/2024

Nexstim Plc Publishes 2023 Annual Report

Company announcement, Helsinki, 6 March 2024 at 1 PM (EET) Nexstim Plc Publishes 2023 Annual Report Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces the publication of its 2023 Annual Report. These documents are available under the "Investors" section of the Company's website atnexstim.com/investors/financial-reports-and-presentations.The Annual Report includes the Report of the Board of Directors, Parent Company and Consolidated Financial Statements as…
Nasdaq GlobeNewswire
06/03/2024

The sixth Alma Academy was successfully held in Barcelona attended by physicians…

The event included live demonstration sessions with Alma's award-winning products such as the flagship Harmony XL Pro, a holistic device for dozens of aesthetic indications, Alma Hybrid, a groundbreaking concept for skin rejuvenation and scar treatments, and Alma PrimeX, providing a superior whole-body experience. The event included live demonstration sessions with Alma's award-winning products such as the flagship Harmony XL Pro, a holistic device for dozens of aesthetic indications, Alma...
PR Newswire
06/03/2024

Novo Nordisk Foundation awarded more than DKK 9.1 billion for purposes…

The Foundation's activities are guided by the belief that science and innovation hold the key to tackling some of the global challenges of our time. The Foundation's activities are guided by the belief that science and innovation hold the key to tackling some of the global challenges of our time. "From fossil-driven climate change and broken agri-food systems to the silent pandemic of drug-resistant infections and the global spread of cardiometabolic diseases, we are committed to…
PR Newswire
06/03/2024

"All United for MG" coalition launches a petition to advocate change in…

gMG is recognized as a rare chronic autoimmune disease that imposes substantial challenges on the majority of individuals affected. It causes complex and chronic physical symptoms that weaken the body's muscles and can be potentially life-threatening. Affecting facial expressions, vision, speech, chewing, swallowing, and breathing, it makes daily movements exhausting and challenging. As a rare disease, it remains difficult and time-consuming to diagnose. gMG is recognized as a rare chronic...
PR Newswire
06/03/2024

Changes in BBS-Bioactive Bone Substitutes Plc's Management Team

BBS-Bioactive Bone Substitutes Plc, Company announcement, 6 March 2024 at 11:15 a.m.Changes in the BBS-Bioactive Bone Substitutes Plc's Management Team Oy Jamerco Ltd. has terminated its service contract with BBS-Bioactive Bone Substitutes Ltd (“BBS”). As a result, Jari Kortesluoma's position as the CFO and member of the management team will end.Kortesluoma will fulfill the responsibilities of CFO throughout the two-month notice period.BBS is currently in the process of searching for...
Nasdaq GlobeNewswire
06/03/2024

Health technology leader Philips recognized as Clarivate Top 100 Global…

Company's innovative products and solutions improved the lives of 1.9 billion people in 2023Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has been included in the 2024 Clarivate Top 100 Global Innovator™ list . Philips' global R&D programs and collaborations aim to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home...
Nasdaq GlobeNewswire
06/03/2024

Asceneuron Expands Scientific Advisory Board with World Leading Experts in…

ASN51 has demonstrated its potential as a pathbreaker to halt disease progression in tau-mediated neurodegenerative diseases with its safe and well tolerated profile and sustained high central enzyme occupancy. In the field of Alzheimer's disease, ASN51 has the potential to change the treatment paradigm for patients when it commences a Phase II clinical trial in the second half of 2024. ASN51 has demonstrated its potential as a pathbreaker to halt disease progression in tau-mediated...
PR Newswire
06/03/2024

Multi-site university health network in the US chooses cloud service from Sectra…

Isaac Zaworski, President of Sectra Inc., emphasizes, "I am proud to be able to offer a solution that helps hospitals deal with both growing imaging volumes as well as cyberthreats. Our experience in assisting large health networks is key when helping customers on their cloud journey." Isaac Zaworski, President of Sectra Inc., emphasizes, "I am proud to be able to offer a solution that helps hospitals deal with both growing imaging volumes as well as cyberthreats. Our experience…
PR Newswire
06/03/2024

Calliditas announces an additional seven year orphan drug exclusivity period for…

"We are delighted to have seven years of market exclusivity expiring in December 2030 for TARPEYO in the US, reflecting the new indication based on the long-term data generated," said CEO Renée Aguiar-Lucander. "We are delighted to have seven years of market exclusivity expiring inDecember 2030for TARPEYO in the US, reflecting the new indication based on the long-term data generated," said CEO Renée Aguiar-Lucander. CONTACT: For further information, please contact : Åsa...
PR Newswire
06/03/2024

VALNEVA Declaration of shares and voting rights - February 29, 2024

VALNEVADeclaration of shares and voting rightsFebruary 29, 2024__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: March 6, 2024 Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of...
Nasdaq GlobeNewswire
06/03/2024

Virbac to take a leading position in Japan through the acquisition of Sasaeah

Virbac announces that it has signed a definitive agreement with ORIX Corporation for the acquisition of its animal health subsidiary Sasaeah for an enterprise value of approximately €280 million. Formed through the combination of two legacy animal health providers (Fujita Pharmaceutical Co. Ltd. and Kyoto Biken Laboratories Inc.) under the stewardship of ORIX Corporation, Sasaeah generates annual revenues of about €75 million, of which 50% from vaccines. With strong footholds in...
Nasdaq GlobeNewswire
06/03/2024

TVM Capital Healthcare Announces the Opening of Baraya Extended Care's First…

Saudi Arabia faces a significant shortage of long-term post-acute care (LTPAC) and rehabilitation beds. Consequently, this area has been identified as a key priority of Vision 2030 to enhance the healthcare sector. As public hospitals are experiencing capacity constraints, dedicated LTPAC and rehabilitation facilities represent a better way to improve patients' lives and alleviate the burden on hospitals. Saudi Arabiafaces a significant shortage of long-term post-acute care (LTPAC) and...
PR Newswire
06/03/2024

Report of transactions of shares and related securities of Bavarian Nordic by…

COPENHAGEN, Denmark, March 6, 2024– Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523.The transactions concern the award of restricted stock units (RSUs) including...
Nasdaq GlobeNewswire
06/03/2024

Bavarian Nordic Publishes Annual Report 2023

COPENHAGEN, Denmark, March 6, 2024– Bavarian Nordic A/S (OMX: BAVA) today published its Annual Report for 2023. The consolidated, audited results were in line with the preliminary results, announced on February 21, 2024, and exceeded prior guidance. The full report is attached as a PDF file and can be found on the Company's website, www.bavarian-nordic.com .Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “Delivering our best-ever financial results in...
Nasdaq GlobeNewswire
06/03/2024
Altri  Comunicati